| Literature DB >> 30891139 |
Fabienne Gourand1, Delphine Patin1, Axelle Henry2, Méziane Ibazizène1, Martine Dhilly1, Fabien Fillesoye1, Olivier Tirel1, Mihaela-Liliana Tintas1, Cyril Papamicaël2, Vincent Levacher2, Louisa Barré1.
Abstract
The norepinephrine transporter (NET) plays an important role in neurotransmission and is involved in a multitude of psychiatric and neurodegenerative diseases. [123I/131I]meta-iodobenzylguanidine (MIBG) is a widely used radiotracer in the diagnosis and follow-up of peripheral neuroendocrine tumors overexpressing the norepinephrine transporter. MIBG does not cross the blood-brain barrier (BBB), and we have demonstrated the "proof-of-concept" that 1,4-dihydroquinoline/quinolinium salt as chemical delivery system (CDS) is a promising tool to deliver MIBG to the brain. To improve BBB passage, various substituents on the 1,4-dihydroquinoline moiety and a linker between CDS and MIBG were added. A series of CDS-MIBG 1a-d was synthesized, labeled with carbon-11, and evaluated in vivo into rats. The in vivo results demonstrated that, although adding substituents on CDS in 1a-c is of no benefit for brain delivery of MIBG, the presence of a linker in CDS-MIBG 1d greatly improved both brain penetration and the release rate of MIBG in the central nervous system.Entities:
Year: 2019 PMID: 30891139 PMCID: PMC6421543 DOI: 10.1021/acsmedchemlett.8b00642
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345